Senti Biosciences (SNTI) AI Stock Analysis

• Market Cap: $26.29M
• Dividend Yield: N/A
• Average Volume (3M): 260.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.07
• Revenue Growth: N/A
• EPS Growth: 78.60%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.69
• Shares Outstanding: 26,290,838
• 10 Day Avg. Volume: 505,690
• 30 Day Avg. Volume: 260,000
• PEG Ratio: <0.01
• Price to Book (P/B): 0.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.39
• Enterprise Value/Market Cap: 1.68
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -11.51
• Enterprise Value/Ebitda: -0.99
• 1Y Price Target: $12.50
• Price Target Upside: 1150.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $1.00 ▲(0.00% Upside)

The score is held down primarily by very weak financial performance (no meaningful revenue, substantial losses/cash burn, and rising leverage with compressed equity). Technicals also remain bearish with the stock trading below major moving averages, partially offset by near-oversold RSI. A positive clinical-data/RMAT corporate event provides upside optionality but does not offset the current funding and profitability risks.

Positive Factors

Promising Trial Data

The promising Phase 1 trial data for SENTI-202 enhances Senti Biosciences' market position in oncology therapies, potentially leading to future revenue streams and partnerships if further trials succeed.

Strategic Leadership Changes

The appointment of a new CFO with extensive financial leadership experience is expected to strengthen financial strategy and operations, supporting long-term growth and clinical development.

Board Expansion

Expanding the board with experienced members enhances governance and strategic oversight, potentially improving decision-making and attracting new talent, which is crucial for long-term success.

Negative Factors

Financial Instability

Ongoing financial instability, marked by continuous losses and negative cash flow, threatens Senti's ability to sustain operations without significant revenue improvement or cost management.

High Leverage

High leverage, indicated by negative equity and reliance on debt, poses risks to financial stability, potentially limiting strategic flexibility and increasing vulnerability to economic downturns.

Negative Cash Flow

Negative cash flow from operations indicates a cash burn issue, necessitating additional financing to sustain operations, which could dilute existing shareholders and strain resources.

Senti Biosciences Business Overview & Revenue Model

Company Description

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.

How the Company Makes Money

Senti Biosciences primarily generates revenue through partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These agreements often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies using Senti's technology platforms. Additionally, the company may receive government grants and funding from research institutions to support its innovative research and development efforts. Another potential revenue stream includes the direct commercialization of its proprietary cell and gene therapies, although this is typically contingent upon successful clinical trials and regulatory approval.

Senti Biosciences Financial Statement Overview

Summary

Financials are weak: revenue is effectively zero, losses are large and persistent (TTM net loss ~-$47.6M), and cash burn remains heavy (TTM FCF ~-$50.3M). Balance-sheet risk has increased as equity has shrunk (~$8.1M) while debt is elevated (~$30.1M), resulting in high leverage (~3.7x debt-to-equity).

Income Statement

The income statement remains weak: revenue is effectively zero in 2024 (annual) and in TTM (Trailing-Twelve-Months), and losses are large and persistent (TTM net loss of about $47.6M; annual net losses ranging roughly $19.9M–$71.1M over 2020–2024). Margins are highly volatile and not yet indicative of a scalable commercial model, with recent periods showing deeply negative profitability despite some year-to-year loss improvement at times.

Balance Sheet

Leverage has increased materially as equity has declined: total debt is ~$30.1M in TTM (Trailing-Twelve-Months) while stockholders’ equity is only ~$8.1M, driving a high debt-to-equity of ~3.7x (vs. ~1.3x in 2024 and much lower levels in earlier years). Total assets have also stepped down versus prior years, and returns on equity are strongly negative, reflecting ongoing losses and a shrinking capital cushion.

Cash Flow

Cash generation is pressured by heavy burn: TTM (Trailing-Twelve-Months) operating cash flow is about -$50.1M and free cash flow about -$50.3M, both consistently negative across the period shown. A positive free-cash-flow growth rate in TTM (Trailing-Twelve-Months) suggests burn improved versus the prior comparison period, but free cash flow still broadly tracks net losses (free cash flow to net income ~1.0x), indicating limited near-term self-funding capacity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	1.98M	3.29M	2.29M	394.00K
Gross Profit	-3.84M	0.00	1.98M	3.29M	2.29M	394.00K
EBITDA	-44.56M	-54.88M	-61.34M	-58.16M	-37.44M	-22.71M
Net Income	-47.58M	-52.79M	-71.06M	-58.21M	-55.32M	-19.86M
Balance Sheet
Total Assets	52.69M	97.84M	119.48M	180.79M	96.70M	48.34M
Cash, Cash Equivalents and Short-Term Investments	12.24M	48.28M	35.93M	98.56M	56.03M	30.54M
Total Debt	30.12M	33.64M	37.67M	37.09M	22.73M	14.05M
Total Liabilities	44.56M	72.19M	52.57M	53.53M	36.33M	107.06M
Stockholders Equity	8.12M	25.65M	66.91M	127.26M	60.38M	-58.71M
Cash Flow
Free Cash Flow	-50.28M	-41.42M	-64.43M	-76.27M	-40.18M	-25.33M
Operating Cash Flow	-50.07M	-41.40M	-52.40M	-34.90M	-34.63M	-24.17M
Investing Cash Flow	-195.00K	34.00K	30.08M	-81.96M	-5.54M	11.36M
Financing Cash Flow	52.01M	53.73M	779.00K	118.55M	68.44M	38.05M

Senti Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNTI, the sentiment is Negative. The current price of 1 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.40, and below the 200-day MA of 2.04, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 37.10 is Neutral, neither overbought nor oversold. The STOCH value of 5.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNTI.

Senti Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNTI	48 Neutral	$26.29M	-0.30	-394.62%	―	―	78.60%
KPTI	48 Neutral	$119.38M	-0.45	―	―	-3.98%	-29.94%
TVRD	46 Neutral	$37.24M	-0.40	-97.61%	―	-53.67%	86.75%
BRNS	44 Neutral	$29.80M	-0.39	-62.30%	―	-100.00%	-26.30%
IOBT	41 Neutral	$20.87M	-0.22	-240.48%	―	―	2.36%
PSTV	40 Underperform	$40.69M	-0.12	―	―	-8.16%	22.44%

Senti Biosciences Corporate Events

Senti Biosciences Reports Promising Phase 1 Trial Results

On December 9, 2025, Senti Biosciences announced initial clinical data from a Phase 1 trial of SENTI-202, a novel cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial results showed promising efficacy and safety, with a 50% overall response rate and 42% complete remission rate. The therapy’s novel mechanism selectively targets cancer cells while sparing healthy cells, and the FDA granted it Regenerative Medicine Advanced Therapy designation, supporting its potential for rapid advancement into pivotal studies.

The most recent analyst rating on (SNTI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Senti Biosciences stock, see the SNTI Stock Forecast page.